157 related articles for article (PubMed ID: 38103196)
1. Protocol for generation of humanized HCC mouse model and cancer-driver mutations using CRISPR-Cas9.
Zhu Y; Tahara SM; Tsukamoto H; Machida K
STAR Protoc; 2023 Dec; 4(4):102389. PubMed ID: 38103196
[TBL] [Abstract][Full Text] [Related]
2. CRISPR/Cas9 Engineering of Adult Mouse Liver Demonstrates That the Dnajb1-Prkaca Gene Fusion Is Sufficient to Induce Tumors Resembling Fibrolamellar Hepatocellular Carcinoma.
Engelholm LH; Riaz A; Serra D; Dagnæs-Hansen F; Johansen JV; Santoni-Rugiu E; Hansen SH; Niola F; Frödin M
Gastroenterology; 2017 Dec; 153(6):1662-1673.e10. PubMed ID: 28923495
[TBL] [Abstract][Full Text] [Related]
3. CRISPR/Cas9-mediated knockout of NSD1 suppresses the hepatocellular carcinoma development via the NSD1/H3/Wnt10b signaling pathway.
Zhang S; Zhang F; Chen Q; Wan C; Xiong J; Xu J
J Exp Clin Cancer Res; 2019 Nov; 38(1):467. PubMed ID: 31727171
[TBL] [Abstract][Full Text] [Related]
4. Generation of mouse models carrying B cell restricted single or multiplexed loss-of-function mutations through CRISPR-Cas9 gene editing.
Ten Hacken E; Gruber M; Hernández-Sánchez M; Hoffmann GB; Baranowski K; Redd RA; Clement K; Livak K; Wu CJ
STAR Protoc; 2023 Dec; 4(4):102165. PubMed ID: 37729058
[TBL] [Abstract][Full Text] [Related]
5. Generation of genetically tailored porcine liver cancer cells by CRISPR/Cas9 editing.
Elkhadragy L; Regan MR; M Totura W; Goli KD; Patel S; Garcia K; Stewart M; Schook LB; Gaba RC; Schachtschneider KM
Biotechniques; 2021 Jan; 70(1):37-48. PubMed ID: 33222517
[TBL] [Abstract][Full Text] [Related]
6. Notch activity characterizes a common hepatocellular carcinoma subtype with unique molecular and clinicopathologic features.
Zhu C; Ho YJ; Salomao MA; Dapito DH; Bartolome A; Schwabe RF; Lee JS; Lowe SW; Pajvani UB
J Hepatol; 2021 Mar; 74(3):613-626. PubMed ID: 33038431
[TBL] [Abstract][Full Text] [Related]
7. An Orthotopic Implantation Mouse Model of Hepatocellular Carcinoma with Underlying Liver Steatosis.
Kasashima H; Duran A; Cid-Diaz T; Kudo Y; Diaz-Meco MT; Moscat J
STAR Protoc; 2020 Dec; 1(3):100185. PubMed ID: 33377079
[TBL] [Abstract][Full Text] [Related]
8. CRISPR/Cas9 somatic multiplex-mutagenesis for high-throughput functional cancer genomics in mice.
Weber J; Öllinger R; Friedrich M; Ehmer U; Barenboim M; Steiger K; Heid I; Mueller S; Maresch R; Engleitner T; Gross N; Geumann U; Fu B; Segler A; Yuan D; Lange S; Strong A; de la Rosa J; Esposito I; Liu P; Cadiñanos J; Vassiliou GS; Schmid RM; Schneider G; Unger K; Yang F; Braren R; Heikenwälder M; Varela I; Saur D; Bradley A; Rad R
Proc Natl Acad Sci U S A; 2015 Nov; 112(45):13982-7. PubMed ID: 26508638
[TBL] [Abstract][Full Text] [Related]
9. Knockout of NCOA5 impairs proliferation and migration of hepatocellular carcinoma cells by suppressing epithelial-to-mesenchymal transition.
He J; Zhang W; Li A; Chen F; Luo R
Biochem Biophys Res Commun; 2018 Jun; 500(2):177-183. PubMed ID: 29626478
[TBL] [Abstract][Full Text] [Related]
10. Description of CRISPR/Cas9 development and its prospect in hepatocellular carcinoma treatment.
Wu X; Ma W; Mei C; Chen X; Yao Y; Liu Y; Qin X; Yuan Y
J Exp Clin Cancer Res; 2020 Jun; 39(1):97. PubMed ID: 32487115
[TBL] [Abstract][Full Text] [Related]
11. Protocol for Efficient CRISPR/Cas9/AAV-Mediated Homologous Recombination in Mouse Hematopoietic Stem and Progenitor Cells.
Tran NT; Trombke J; Rajewsky K; Chu VT
STAR Protoc; 2020 Jun; 1(1):100028. PubMed ID: 32685932
[TBL] [Abstract][Full Text] [Related]
12. Intrinsic activation of β-catenin signaling by CRISPR/Cas9-mediated exon skipping contributes to immune evasion in hepatocellular carcinoma.
Akasu M; Shimada S; Kabashima A; Akiyama Y; Shimokawa M; Akahoshi K; Kudo A; Yamaoka S; Tanabe M; Tanaka S
Sci Rep; 2021 Aug; 11(1):16732. PubMed ID: 34429454
[TBL] [Abstract][Full Text] [Related]
13. A review of the literature on the use of CRISPR/Cas9 gene therapy to treat hepatocellular carcinoma.
Amjad E; Pezzani R; Sokouti B
Oncol Res; 2024; 32(3):439-461. PubMed ID: 38361756
[TBL] [Abstract][Full Text] [Related]
14. LMNA functions as an oncogene in hepatocellular carcinoma by regulating the proliferation and migration ability.
Liu H; Li D; Zhou L; Kan S; He G; Zhou K; Wang L; Chen M; Shu W
J Cell Mol Med; 2020 Oct; 24(20):12008-12019. PubMed ID: 32896989
[TBL] [Abstract][Full Text] [Related]
15. CRISPR/Cas9‑mediated hypoxia inducible factor‑1α knockout enhances the antitumor effect of transarterial embolization in hepatocellular carcinoma.
Liu Q; Fan D; Adah D; Wu Z; Liu R; Yan QT; Zhang Y; Du ZY; Wang D; Li Y; Bao SY; Liu LP
Oncol Rep; 2018 Nov; 40(5):2547-2557. PubMed ID: 30226584
[TBL] [Abstract][Full Text] [Related]
16. Exploiting CRISPR/Cas9 to engineer precise segmental deletions in mouse embryonic stem cells.
Elango R; Panday A; Willis NA; Scully R
STAR Protoc; 2022 Sep; 3(3):101551. PubMed ID: 36042887
[TBL] [Abstract][Full Text] [Related]
17. CRISPR screens uncover protective effect of PSTK as a regulator of chemotherapy-induced ferroptosis in hepatocellular carcinoma.
Chen Y; Li L; Lan J; Cui Y; Rao X; Zhao J; Xing T; Ju G; Song G; Lou J; Liang J
Mol Cancer; 2022 Jan; 21(1):11. PubMed ID: 34983546
[TBL] [Abstract][Full Text] [Related]
18. [Establishment of Cas9 stably expressed human hepatocellular carcinoma and cholangiocarcinoma cell lines].
Zuo CX; Bian XC; Yang ZL; Feng HL; Zhou FY; Liu YQ
Zhonghua Zhong Liu Za Zhi; 2018 Aug; 40(8):572-579. PubMed ID: 30139026
[No Abstract] [Full Text] [Related]
19. Genome-Wide CRISPR/Cas9 Library Screening Revealed Dietary Restriction of Glutamine in Combination with Inhibition of Pyruvate Metabolism as Effective Liver Cancer Treatment.
Yang C; Lee D; Zhang MS; Tse AP; Wei L; Bao MH; Wong BP; Chan CY; Yuen VW; Chen Y; Wong CC
Adv Sci (Weinh); 2022 Dec; 9(34):e2202104. PubMed ID: 36310121
[TBL] [Abstract][Full Text] [Related]
20. Optimized CRISPR/Cas9-mediated single nucleotide mutation in adherent cancer cell lines.
Gao P; Dong X; Wang Y; Wei GH
STAR Protoc; 2021 Jun; 2(2):100419. PubMed ID: 33870225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
